Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.

@article{Sandstrm2013IndividualizedDO,
  title={Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.},
  author={Mattias Sandstr{\"o}m and Ulrike Garske-Rom{\'a}n and Dan Granberg and Silvia Johansson and Charles Widstr{\"o}m and B. Anders Eriksson and Anders Sundin and Hans Lundqvist and Mark Lubberink},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2013},
  volume={54 1},
  pages={33-41}
}
UNLABELLED The organs at risk in radionuclide therapy with (177)Lu-octreotate are the bone marrow and the kidneys. The primary aim of this study was to develop an individualized dosimetry protocol for the bone marrow. The secondary aim was to identify those patients, undergoing fractionated therapy with 7.4 GBq/cycle, who first reached an accumulated dose… CONTINUE READING